UroGen Pharma (URGN) Tops Q3 EPS by 3c

UroGen Pharma (NASDAQ: URGN) reported Q3 EPS of ($1.13), $0.03 better than the analyst estimate of ($1.16). Revenue for the quarter came in at $16.01 million versus the consensus estimate of $20.15 million.

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Calamp Corp. (CAMP) Misses Q2 EPS by 33c
• Tenon Medical (TNON) Misses Q2 EPS by 395c